MetaVia Inc. (NASDAQ:MTVA – Free Report) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of MetaVia in a research note issued on Monday, March 31st. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings of ($0.57) per share for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Small Cap also issued estimates for MetaVia’s Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.26) EPS, FY2026 earnings at ($1.65) EPS and FY2027 earnings at ($1.53) EPS.
Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of MetaVia in a research report on Friday, March 21st.
MetaVia Trading Down 2.2 %
MTVA opened at $1.54 on Wednesday. The company has a fifty day moving average price of $1.63. MetaVia has a 52 week low of $1.29 and a 52 week high of $5.30.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- Retail Stocks Investing, Explained
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- Investing in Construction Stocks
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Start Investing in Real Estate
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
